Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Mydecine Innovations Group (TSE:MYCO)
CNQX:MYCO
Holding TSE:MYCO?
Track your performance easily
MYCO Stock Chart & Stats
Day’s RangeC$0 - C$0
52-Week Range<C$0.01 - C$0.14
Previous CloseC$0.01
Volume1.29K
Average Volume (3M)67.72K
Market Cap
C$617.55K
Enterprise ValueC$6.75M
Total Cash (Recent Filing)C$13.61K
Total Debt (Recent Filing)C$6.14M
Price to Earnings (P/E)―
Beta1.89
Next Earnings
Mar 28, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding61,755,398
10 Day Avg. Volume86,573
30 Day Avg. Volume67,723
Standard Deviation0.36
R-Squared0.01
Alpha-0.17
Financial Highlights & Ratios
Price to Book (P/B)-0.04
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-15.80
P/FCF Ratio0.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Mydecine Innovations Group News
PremiumCompany Announcements
Mydecine Shares Suspended on Aquis Market
PremiumCompany Announcements
Mydecine Completes Key Financial Filings
PremiumCompany Announcements
Mydecine Delays Financial Filings, Postpones AGM
PremiumCompany Announcements
Mydecine Delays Financial Reports, Trades ContinuePremiumCompany Announcements
Mydecine Reports Delay and Progress Amid MCTO
PremiumCompany Announcements
Mydecine Requests Extra Time for Financial Filings
PremiumCompany Announcements
Mydecine Innovations Faces Trading RestrictionsPremiumCompany Announcements
Mydecine Announces Restructuring and CEO InvestmentOptions Prices
Currently, No data available
---
Ownership Overview
2.39% Insiders
<0.01% Other Institutional Investors
97.61% Public Companies and
Individual Investors
MYCO FAQ
What was Mydecine Innovations Group’s price range in the past 12 months?
Mydecine Innovations Group lowest stock price was <C$0.01 and its highest was C$0.14 in the past 12 months.
What is Mydecine Innovations Group’s market cap?
Currently, no data Available
When is Mydecine Innovations Group’s upcoming earnings report date?
Mydecine Innovations Group’s upcoming earnings report date is Mar 28, 2025 which is in 125 days.
How were Mydecine Innovations Group’s earnings last quarter?
Mydecine Innovations Group released its earnings results on Nov 12, 2024. The company reported -C$0.032 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.032.
Is Mydecine Innovations Group overvalued?
According to Wall Street analysts Mydecine Innovations Group’s price is currently Overvalued.
Does Mydecine Innovations Group pay dividends?
Mydecine Innovations Group does not currently pay dividends.
What is Mydecine Innovations Group’s EPS estimate?
Mydecine Innovations Group’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mydecine Innovations Group have?
Mydecine Innovations Group has 61,755,398 shares outstanding.
What happened to Mydecine Innovations Group’s price movement after its last earnings report?
Mydecine Innovations Group reported an EPS of -C$0.032 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Mydecine Innovations Group?
Currently, no hedge funds are holding shares in TSE:MYCO
---
Mydecine Innovations Group Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
―
20 days / 200 days
Momentum
-92.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-96.00%
Trailing 12-Months
Company Description
Mydecine Innovations Group
Mydecine Innovations Group Inc is a biopharma and life sciences company. It is committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use. Reinforcing Mydecine's commitment to mental health solutions is underpinned by the company's three main focuses: Clinical Trials focusing on Veterans, EMS, and First Responders with a PTSD indication; Research and Development building a robust portfolio of intellectual property around drug discovery and unique delivery mechanisms with relevant use patents and future patent applications and Modern technology utilizing for better clinical trial management and mental health wellbeing.
---
Technical Analysis
---